Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11027155 | 0.98 | HPGDS (0.54) | HPGDSP4HTMKDM4ETDP1TP53 | |
| SCHEMBL28576114 | 0.85 | P4HTM (0.70) | HPGDSP4HTMKDM4ETDP1TP53 | |
| SCHEMBL1671397 | 0.83 | KDM4E (0.61) | HPGDSP4HTMKDM4ETDP1TP53 | |
| SCHEMBL11891928 | 0.81 | HPGDS (0.55) | HPGDSP4HTMKDM4ETDP1TP53 | |
| Hydrochloric Acid SCHEMBL3216270 | 0.81 | HPGDS (0.59) | HPGDSP4HTMKDM4ETDP1TP53 | |
| SCHEMBL3408513 | 0.81 | HPGDS (0.55) | HPGDSP4HTMKDM4ETDP1TP53 | |
| SCHEMBL204707 | 0.78 | SLC6A7 (0.52) | P4HTMKDM4ELMNACYP1A2POLB | |
| SCHEMBL29688109 | 0.78 | SLC6A7 (0.52) | P4HTMKDM4ELMNACYP1A2POLB | |
| SCHEMBL3217944 | 0.77 | HPGDS (0.55) | HPGDSP4HTMKDM4ETDP1LMNA | |
| SCHEMBL25913367 | 0.77 | HPGDS (0.55) | HPGDSP4HTMKDM4ETDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2021-10-28 | — | — | US | disclosed |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2020-12-10 | — | — | US | disclosed |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-08-29 | — | — | US | disclosed |
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI SA (FR) | 2019-01-03 | — | — | US | disclosed |
| US-9937175-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2018-04-10 | — | — | US | disclosed |
| US-9937175-B2 | Phenyloxadiazole derivatives as PGDS inhibitors | SANOFI (FR) | 2018-04-10 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI- AVENTIS (FR) | 2017-08-17 | — | — | US | disclosed |
| CN-101646656-B | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI AVENTIS SPA | 2013-08-14 | — | — | CN | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI (FR) | 2012-07-26 | — | — | US | disclosed |
| WO-2011044307-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2011-04-14 | — | — | WO | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| CN-101646656-A | Pyrimidine hydrazide compounds as the PGDS inhibitor | SANOFI AVENTIS FR | 2010-02-10 | — | — | CN | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000845-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 6/4885P4HTM 1200/4885KDM4E 3936/4885 |
| US-20200383982-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 6/4885P4HTM 1200/4885KDM4E 3936/4885 |
| US-20190262338-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 8/4885P4HTM 1213/4885KDM4E 3920/4885 |
| US-20120190695-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 6/4885P4HTM 1200/4885KDM4E 3936/4885 |
| US-20230190747-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 6/4885P4HTM 1200/4885KDM4E 3936/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885P4HTM 228/4885KDM4E 2494/4885 |
| US-20210330671-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 7/4885P4HTM 1221/4885KDM4E 3914/4885 |
| US-20170231990-A1 | PHENYLOXADIAZOLE DERIVATIVES AS PGDS INHIBITORS | PTGER1, PTGIS, PTGDR | HPGDS 6/4885P4HTM 1200/4885KDM4E 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.